Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform PHOENIX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage leader in regenerative and cellular innovation, today announced the official launch of its BioDefense Inc. Veterans Initiative , believed to be a first-of-its-kind national program to... Read More

PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. , (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company... Read More

Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today issued a Letter to Shareholders from Timothy Warbington, Co-Founder... Read More

Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical’s Similar Research Focus PHOENIX, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today congratulated Mary E.... Read More

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational therapy, CELZ-201-DDT , for the treatment of degenerative disc disease (DDD), a major cause of chronic... Read More

PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”) , a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “ Prevention and/or Treatment of Type 1 Diabetes by... Read More

PHOENIX / Mar 27, 2024 / Business Wire / Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its Form 10-K on March 22, 2024. “In the past year our achievements have been... Read More

PHOENIX / Mar 07, 2024 / Business Wire / Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ) , a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing T1D in high-risk individuals. This... Read More

PHOENIX / Mar 06, 2024 / Business Wire / Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for CELZ-101, ImmCelz TM . This cutting-edge... Read More

PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This study aims to determine the safety, efficacy and tolerability of CELZ-201-DDT, a proprietary, ready-to-use cell line developed by the company. The trial... Read More

Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt PHOENIX , Nov. 15, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided... Read More

Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX , Oct. 10, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology,... Read More

PHOENIX , Sept. 19, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company to proceed with a Phase 1/2 clinical trial of StemSpine ®... Read More

PHOENIX , June 28, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that on June 27, 2023 it received written notice from The Nasdaq Stock Market LLC informing the Company that it has regained... Read More

Continued Advancements in Developing Regenerative Therapeutics While Maintaining Strong Financial Position PHOENIX , June 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided an update on recent... Read More

PHOENIX , June 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up to $2... Read More

PHOENIX , June 9, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 10 (the... Read More

PHOENIX , May 31, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that it has received confirmation that Greenstone Biosciences Inc. in Palo Alto, CA has successfully developed a human induced... Read More

Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders PHOENIX , May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced significant advances in the ongoing... Read More

Study Demonstrated Significant Efficacy and No Serious Adverse Events PHOENIX , May 18, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced positive top line pilot study results for the StemSpine ®... Read More

One-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients Using CELZ-001 for Treating Type 2 Diabetes PHOENIX , April 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ) , a leading biotechnology company focused on a regenerative approach to immunotherapy, urology, gynecology, and orthopedics, today... Read More

PHOENIX , April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced the filing of its Form 10-K on March 31, 2023 for the year ended December 31, 2022 (FY 2022) and provided a summary of the... Read More

PHOENIX , March 23, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) , a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for the treatment of Brittle Type 1 Diabetes using its... Read More

Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOENIX , March 21, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced third party validation... Read More

PHOENIX / Mar 07, 2023 / Business Wire / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has engaged Syneos Health (NASDAQ: SYNH) as the contract research organization (CRO) for its upcoming Phase 1/2... Read More

PHOENIX / Feb 14, 2023 / Business Wire / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-up data for the Company's StemSpine® pilot study. The three-year data demonstrates continued... Read More

Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX , Feb. 8, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today... Read More

Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy,... Read More

Creative Medical Technology Holdings, Inc. (OTC-CELZ) (the "Company"), a commercial stage biotechnology company focused on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications, today announced its intention to effect... Read More

Creative Medical Technology Holdings Inc. (OTC-CELZ) announced today proof of concept data demonstrating the ability of its next generation ImmCelz ™ immunotherapy product to "reprogram" patient immune cells using the Company's patent pending "ex vivo cell-free" reprogramming protocol. The study was performed at cGMP Advanced... Read More

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called "exosomes" secreted by cells of its MyeloCelz™ platform and their use in the treatment of type 1 diabetes. The patent additionally covers combinations of these antigen-specific exosomes together... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has engaged Elite Med Listings Inc. to help accelerate the adoption of CaverStem ® . Elite Med Listings is an agency... Read More

Creative Medical Technology Holdings, Inc . ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional investors for gross proceeds of approximately $3,788,000 . The definitive agreements provide for the private placement of 15% Original... Read More

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today the launching of its second Regenerative Immunology product, MyeloCelz™. In contrast to the Company's ImmCelz™ product, which utilizes primarily T cells and B cells to induce activation of the body's own stem cells and healing processes, MyeloCelz™ utilizes... Read More

Creative Medical Technology Holdings (OTC-CELZ) announced today recruitment of Dr. Courtney Bartlett to lead clinical development of the Company's pipeline of therapeutic products. Dr. Bartlett has been heading clinical research efforts for more than a decade in the area of cell and gene therapy. She was co-Investigator on... Read More

Creative Medical Technology Holdings, Inc. (OTC - CELZ), announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit today Thursday, June 17, 2021 at 12:00pm Eastern Standard Time and will consist of a 20-minute formal description of the Company followed by a 20-minute Q&A session... Read More

Creative Medical Technology Holdings , trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with new data indicating that the Company's ImmCelz® personalized cell therapy product and myeloid suppressor cells suppress autoimmune diabetes. In a series of experiments,... Read More

Creative Medical Technology Holdings , trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease. Using the well established MPTP mouse model of the disease, it was demonstrated that administration of ImmCelz® inhibited onset of... Read More

Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs Timothy Henry , Santosh Kesari , Ceagan Du, and Boris Reznik in accelerating advancement of its ImmCelz® Regenerative Immunotherapy... Read More

Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA regarding necessary modifications to IND #27375 for using ImmCelz® regenerative immunotherapy for the treatment of stroke. The Company's ImmCelz® product utilizes a patient's own blood cells that have been "reprogrammed" in the laboratory by culturing with established universal donor... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced its intent to launch Virtual Physician™ focused on telehealth solutions for regenerative medicine this summer. The... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that the FDA issued IND Number 27375 to the Company in connection with its Clinical Trial application to use ImmCelz ®... Read More

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today announced that it has started recruitment of clinical sites for StemSpine®. StemSpine® , the company's patented Regenerative... Read More

Creative Medical Technology Holdings (OTC - CELZ) announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease. Evaluation of patients at 30,60 90, 180, and 360... Read More

Creative Medical Technology Holdings (OTC-CELZ) announced today that due to COVID related technical changes in the FDA's submission requirements, the Company's ImmCelz® Investigational New Drug Application (IND) for the treatment of Stroke will be resubmitted to the FDA in electronic form to comply with such requirements.... Read More

Creative Medical Technology Holdings , Inc. (OTC – CELZ) announced today filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs. ImmCelz® is a cellular therapy that prevents pathological immunity and inflammation while at the same time inducing regeneration of damaged tissue. Mechanistically ImmCelz® has been shown to function through stimulation... Read More